Li Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(195 intermediate revisions by 2 users not shown)
Line 6: Line 6:
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
<div style="float:left;margin-left:0.3em;margin-right:0.7em">


== '''Welcome to the Computational Genomics Lab''' ==  
== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  


[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
Line 13: Line 13:


| rowspan="2" width="40%" style="border: 2px dashed #6688AA; background-color:#ffffff; padding:1em;" valign="top"|
| rowspan="2" width="40%" style="border: 2px dashed #6688AA; background-color:#ffffff; padding:1em;" valign="top"|
==Recent News==
==Recent News==
. 12/2010: Liguo's fly RNA-seq paper has been published in  '''Genome Research'''.
. 08/2015: Kaifu's Cancer Big-data analysis paper is published in '''Nature Genetics'''. This work links broad H3K4me3 to pan-cancer tumor suppressors. See Nature Editor’s [http://blogs.nature.com/freeassociation/2015/08/methylation-marks-tumor-suppressors.html Blog] and Chinese Report in [http://www.ebiotrade.com/newsf/2015-8/2015825165005119.htm ebiotrade.com]
 
. 07/2015: Wei will become a regular member of the '''NIH GCAT''' (Genomics, Computational Biology and Technology) study section.
 
. 06/2015: Kaifu will start his '''tenure-track faculty''' position at Cornell University & Methodist Hospital. Congratulations!


. 10/2010: A Texas '''CPRIT grant''' has been funded. We will work with Dr. Goodell at BCM to understand DNA Methylgransferase 3B in normal and malignant hematopoiesis.  
. 06/2015: We will receive a '''NEW NIH/NCI R01''' grant (scored at 5%ile) to study 3`UTR alternations in human cancers.


. 08/2010Our '''Pilot Project''' has been funded by a NIH Stem Cell P01 Grant.  
. 03/2015Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to '''PNAS'''.


. 07/2010: The DNA methylation platform comparision paper has been accepted to '''Nature Biotechnology'''.
. 3/2015: We received a NEW '''CPRIT''' grant.


. 06/2010: Hao Zhao will join us as a '''postdoc fellow'''. Hao has a PhD in Computer Science from City University of Hong Kong.  Welcome!
. 01/2015: Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to '''Cell Stem Cell''' -- the 100th paper we published.


. 05/2010Our paper titled "Histone modifications and chromatin organization in prostate cancer" has been accepted by '''Epigenomics'''.
. 12/2014Zheng Xia is awarded a '''Keck fellowship''' in Computational Cancer Biology.


. 01/2010A Texas '''CPRIT grant''' has been funded. We will use ChIP-seq and RNA-seq to analyze Androgen Receptor (AR) function in Prostate Cancer with Dr. Weigel at BCM.
. 11/2014Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in '''Nature Communications'''.


. 01/2010A '''CPRIT multi-investigator planning award''' has been funded. This project will bring together a "dream team" in epigenetics researchWe will direct the bioinformatics component for LONESTAR.
. 09/2014Liguo's ChIP-exo methodology paper (MACE) is accepted to '''Nucleic Acids Research'''.  MACE is recommended by Active Motif as the software solution for the company's new [https://www.activemotif.com/catalog/1050/chip-exo ChIP-exo kit and service].


. 01/2010: Wei Li is an invited speaker in the American Association for Cancer Research (AACR) Special '''Conference on Cancer Epigenetics''' at Puerto Rico.
. 09/2014: Deqiang will start his '''tenure-track assistant professor''' position. Job well done. 


. 12/24/2009Dr.Bert O'Malley's SRC-3 ChIP-seq paper has been accepted by '''Molecular Endocrinology'''. Liguo and Wei are co-authors on the paper.
. 09/2014Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to '''Molecular Cancer Research '''.  


. 12/08/2009Liguo's RNA-seq methodology paper has been accepted by '''PLoS ONE'''. Congratulations Liguo!
. 09/2014Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to '''Cell'''.


. 11/13/2009Wei Li received a '''New Investigator Award''' from the Department of Defense (DOD) Prostate Cancer Research Program (PCRP). Cheers!
. 08/2014:  '''Three Collaborative CPRIT grants''' are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.


. 11/07/2009Wei Li gave a '''Keynote Presentation''' at the Symposium on Advances in Cell Signaling, Cancer Prevention and Therapy at South Padre Island, Texas.
. 06/2014Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to '''Cell Stem Cell '''.  


. 09/29/2009A prestigious '''NIH Challenge grant''' has been funded. We will use ChIP-seq to analyze RXRa binding in mouse liver with Dr. Karpen at Texas Children's Hospital.
. 06/2014Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to '''Molecular Cell '''.  


. 09/17/2009A two-year $2.5 million '''NIH Grand Opportunity (GO) grant''' has been funded. We will study aging epigenomics with Drs. Darlington and Goodell at BCM.
. 02/2014Zheng's brain tumor 3'UTR regulator paper is accepted to '''Nature'''. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.


. 09/15/2009A prestigious '''NIH Challenge grant''' has been funded. We will use RNA-seq to characterize patient cardiac progenitors with Dr. Pu at Harvard Medical School.
. 02/2014Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.


. 06/05/2009Yuanxin's Bisulfite Sequence Mapping paper has been accepted by '''BMC Bioinformatics'''. Congratulations Yuanxin!
. 02/2014Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to '''Cell Stem Cell'''.


. 03/26/2009Wei's paper titled 'Reprogrammed Androgen Receptor Function in Androgen-Independent Prostate Cancer' has been accepted by '''Cell'''.
. 01/2014Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to '''Genome Biology'''.


. 01/2014:  Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to '''Nature'''. This work links transcription elongation to tumor suppression.


[[Image:Banner.jpg‎‎]]


[http://openwetware.org/wiki/Li_Lab:news News Archive]
[http://openwetware.org/wiki/Li_Lab:news News Archive]
Line 56: Line 65:
{|width="*"
{|width="*"
|
|
{| style="width: 100%;  text-align:center;font-size:12px;font-variant: small-caps;width: 18px; " align="center"  
{| style="width: 728px;  text-align:center;font-size:12px;font-variant: small-caps;width: 18px; " align="center"  
|-
|-


Line 72: Line 81:
<div style="border-bottom: 1px dashed #9999CC;">
<div style="border-bottom: 1px dashed #9999CC;">


== '''A Genomic View of Epigenetic and Transcriptional Regulation''' ==
Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have
* '''Published''' more than 75 peer-reviewed papers through solid methodology development and extensive collaboration research, including 28 in '''Nature, Science and Cell''' series.
 
* '''Been well-funded''' by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
* '''Mentored''' the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.
 
We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.


In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.


Our lab is focused on the design and application of statistical and computational algorithms to elucidate global epigenetic and transcriptional regulatory mechanism, by interpreting and integrating data from ChIP-chip/seq, DNA methylation, Nucleosome positioning, Alternative splicing and Motif finding.
* '''Chromatin Factors''': ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..


An elaborate system of epigenetic and transcription regulation is responsible for the morphological and behavioral complexity in higher eukaryotes. This regulatory system consists of diverse trans-acting protein factors, cis-acting regulatory DNA sequences and the underlying epigenomic background, such as histone modifications, DNA methylation and Nucleosome localizations. Recently, Chromatin ImmunoPrecipitation coupled with whole genome tiled microarray (ChIP-chip) and/or next-generation sequencing (Solexa, SOLiD and 454) has evolved as a powerful and unbiased technique to study this genome-wide regulatory system. The application of this technology to multiple factors and/or in multiple conditions allows biologists to study how transcription is differentially regulated in a combinatorial manner. However, it also poses great challenges for the development of effective algorithms, the key link between massive raw data and biological hypotheses.
* '''DNA Methylation''': DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.  


We developed a series of algorithms to reliably detect and annotate ChIP-enriched regions using Next-generation sequencing (MACS; Genome Biology 2008) and Affymetrix whole-genome tiling arrays, including 1) Model-based Analysis of Tiling-arrays (MAT; PNAS 2006) and a hidden Markov model (Bioinformatics 2005) for ChIP-region detection, 2) extreme MApping of OligoNucleotide (xMAN; BMC Genomics 2008) for microarray probe mapping, 3) Cis-regulatory Element Annotation System (CEAS; NAR 2006) for ChIP-region annotation. Since the inception in early 2006, they have been adopted by hundreds of academic users and are now considered as the ChIP-chip data analysis standard in many labs.  We worked with ENCODE consortium to systematically analyze the performance variability introduced in ChIP-chip protocols, array platforms, and analysis methods (Genome Res. 2008). Furthermore, we are also in close collaboration with several labs on identifying global regulation targets of several key transcription factors, including Estrogen Receptor (Cell 2005; Nature Genetics 2006); Androgen Receptor (Molecular Cell 2007; Cell 2009) and FoxA1 (Cell 2008).
* '''Nucleosome Organization''': Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.


We are currently collaborating with many BCM laboratories to use the Next generation sequencing to study 1) Transcription factor binding and histone modifications (ChIP-seq); 2) DNA methylation at single nucleotide resolution (Bisulfite-seq); 3) Nucleosome remodeling (Mnase-seq); 4) Alternative splicing (RNA-seq).  My laboratory also plays an important role in the BCM Epigenomics Data Analysis and Coordination Center for a five-year [http://nihroadmap.nih.gov/epigenomics/referenceepigenomeconsortium.asp NIH Roadmap Epigenomics Program].  
* '''Transcriptome''': chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


[http://sites.google.com/a/bcm.edu/lilab/ Lab Intranet]
[http://sites.google.com/a/bcm.edu/lilab/ Lab Intranet]
[http://openwetware.org/wiki/Li_Lab openwetware]
[http://openwetware.org/wiki/Li_Lab openwetware]

Revision as of 08:23, 26 August 2015

Home        People        Publications        Collaborations        Software        Positions        Contact       


Recent News

. 08/2015: Kaifu's Cancer Big-data analysis paper is published in Nature Genetics. This work links broad H3K4me3 to pan-cancer tumor suppressors. See Nature Editor’s Blog and Chinese Report in ebiotrade.com

. 07/2015: Wei will become a regular member of the NIH GCAT (Genomics, Computational Biology and Technology) study section.

. 06/2015: Kaifu will start his tenure-track faculty position at Cornell University & Methodist Hospital. Congratulations!

. 06/2015: We will receive a NEW NIH/NCI R01 grant (scored at 5%ile) to study 3`UTR alternations in human cancers.

. 03/2015: Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to PNAS.

. 3/2015: We received a NEW CPRIT grant.

. 01/2015: Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to Cell Stem Cell -- the 100th paper we published.

. 12/2014: Zheng Xia is awarded a Keck fellowship in Computational Cancer Biology.

. 11/2014: Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in Nature Communications.

. 09/2014: Liguo's ChIP-exo methodology paper (MACE) is accepted to Nucleic Acids Research. MACE is recommended by Active Motif as the software solution for the company's new ChIP-exo kit and service.

. 09/2014: Deqiang will start his tenure-track assistant professor position. Job well done.

. 09/2014: Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to Molecular Cancer Research .

. 09/2014: Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to Cell.

. 08/2014: Three Collaborative CPRIT grants are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.

. 06/2014: Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to Cell Stem Cell .

. 06/2014: Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to Molecular Cell .

. 02/2014: Zheng's brain tumor 3'UTR regulator paper is accepted to Nature. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.

. 02/2014: Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.

. 02/2014: Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to Cell Stem Cell.

. 01/2014: Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to Genome Biology.

. 01/2014: Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to Nature. This work links transcription elongation to tumor suppression.


News Archive




Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have

  • Published more than 75 peer-reviewed papers through solid methodology development and extensive collaboration research, including 28 in Nature, Science and Cell series.
  • Been well-funded by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
  • Mentored the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.

We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.

In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.

  • Chromatin Factors: ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..
  • DNA Methylation: DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.
  • Nucleosome Organization: Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.
  • Transcriptome: chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


Lab Intranet openwetware


<html> <script type="text/javascript">

 var _gaq = _gaq || [];
 _gaq.push(['_setAccount', 'UA-5924762-2']);
 _gaq.push(['_trackPageview']);
 (function() {
   var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
   ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
   var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
 })();

</script> </html>